يعرض 41 - 50 نتائج من 194 نتيجة بحث عن '"Demidov, L"', وقت الاستعلام: 1.62s تنقيح النتائج
  1. 41
    دورية أكاديمية
    Patient perception of the benefit of a BRAF inhibitor in metastatic melanoma: quality-of-life analyses of the BREAK-3 study comparing dabrafenib with dacarbazine

    المؤلفون: Grob, J.-J., Amonkar, M. M., Martin-Algarra, S., Demidov, L. V., Goodman, V., Grotzinger, K., Haney, P., Kämpgen, E., Karaszewska, B., Mauch, C., Miller Jr., W. H., Millward, M., Mirakhur, B., Rutkowski, P., Chiarion-Sileni, V., Swann, S., Hauschild, A.

    مصطلحات موضوعية: ddc:610

    وصف الملف: application/pdf

    العلاقة: https://opus4.kobv.de/opus4-fau/frontdoor/index/index/docId/7419Test; urn:nbn:de:bvb:29-opus4-74190; https://nbn-resolving.org/urn:nbn:de:bvb:29-opus4-74190Test; https://doi.org/10.1093/annonc/mdu154Test; https://opus4.kobv.de/opus4-fau/files/7419/Grob_patient.pdfTest

    الإتاحة: https://doi.org/10.1093/annonc/mdu154Test
    https://opus4.kobv.de/opus4-fau/frontdoor/index/index/docId/7419Test
    https://nbn-resolving.org/urn:nbn:de:bvb:29-opus4-74190Test
    https://opus4.kobv.de/opus4-fau/files/7419/Grob_patient.pdfTest

    View record in BASE

    أضف إلى المفضلة
  2. 42
    دورية أكاديمية
    Functional and symptom impact of trametinib versus chemotherapy in BRAF V600E advanced or metastatic melanoma: quality-of-life analyses of the METRIC study

    المؤلفون: Schadendorf, D., Amonkar, M. M., Milhem, M., Grotzinger, K., Demidov, L. V., Rutkowski, P., Garbe, C., Dummer, R., Hassel, J. C., Wolter, P., Mohr, P., Trefzer, U., Lefeuvre-Plesse, C., Rutten, A., Steven, N., Ullenhag, G., Sherman, L., Wu, F. S., Patel, K., Casey, M., Robert, C.

    مصطلحات موضوعية: Original article

    وصف الملف: text/html

    العلاقة: http://annonc.oxfordjournals.org/cgi/content/short/mdt580v1Test; http://dx.doi.org/10.1093/annonc/mdt580Test

    الإتاحة: https://doi.org/10.1093/annonc/mdt580Test
    http://annonc.oxfordjournals.org/cgi/content/short/mdt580v1Test

    View record in BASE

    أضف إلى المفضلة
  3. 43
    دورية أكاديمية
    An Update on Overall Survival (Os) and Follow-On Therapies in Break-3, a Phase Iii, Randomized Trial: Dabrafenib (D) Vs. Dacarbazine (Dtic) in Patients (Pts) with Braf V600E Mutation-Positive Metastatic Melanoma (Mm)

    المؤلفون: Hauschild, A., Grobb, J., Demidov, L., Jouary, T., Gutzmer, R., Millward, M., Rutkowski, P., Blank, C., Miller, W., Martin-Algarra, S., Karaszewska, B., Mauch, C., Chiarion Sileni, V., Aktan, G., Haney, P., Jin, F., Legos, J., Swann, S., Chapman, P.

    المصدر: Annals of Oncology ; volume 25, page iv378 ; ISSN 0923-7534

    مصطلحات موضوعية: Oncology, Hematology

    الإتاحة: https://doi.org/10.1093/annonc/mdu344.8Test
    https://api.elsevier.com/content/article/PII:S0923753419525443?httpAccept=text/xmlTest
    https://api.elsevier.com/content/article/PII:S0923753419525443?httpAccept=text/plainTest
    http://academic.oup.com/annonc/article-pdf/25/suppl_4/iv378/9691345/mdu344.8.pdfTest

    View record in BASE

    أضف إلى المفضلة
  4. 44
    MASTERKEY-265: A phase III, randomized, placebo (Pbo)-controlled study of talimogene laherparepvec (T) plus pembrolizumab (P) for unresectable stage IIIB-IVM1c melanoma (MEL)

    المؤلفون: Ribas, A. Chesney, J. Long, G. V. Kirkwood, J. M. and Dummer, R. Puzanov, I. Hoeller, C. Gajewski, T. F. and Gutzmer, R. Rutkowski, P. Demidov, L. Arenberger, P. and Shin, S. J. Ferrucci, P. F. Diede, S. J. Anderson, J. R. and Treichel, S. Chan, E. Hodi, F. S. Gogas, H. J.

    الوصول الحر: https://explore.openaire.eu/search/publication?articleId=od______2127::458c2e4bce13a599d82f5ec24cc47b4eTest
    https://pergamos.lib.uoa.gr/uoa/dl/object/uoadl:3031626Test


    أضف إلى المفضلة
  5. 45
    Cobimetinib plus atezolizumab in BRAFV600 wild-type melanoma: primary results from the randomized phase III IMspire170 study

    المؤلفون: Gogas, H. Dréno, B. Larkin, J. Demidov, L. Stroyakovskiy, D. Eroglu, Z. Francesco Ferrucci, P. Pigozzo, J. Rutkowski, P. Mackiewicz, J. Rooney, I. Voulgari, A. Troutman, S. Pitcher, B. Guo, Y. Yan, Y. Castro, M. Mulla, S. Flaherty, K. Arance, A.

    الوصول الحر: https://explore.openaire.eu/search/publication?articleId=od______2127::4ffcaa298e92105ffd0f42860dd18136Test
    https://pergamos.lib.uoa.gr/uoa/dl/object/uoadl:3102745Test


    أضف إلى المفضلة
  6. 46
    دورية أكاديمية
    Safety and efficacy of nivolumab in challenging subgroups with advanced melanoma who progressed on or after ipilimumab treatment: A single-arm, open-label, phase II study (CheckMate 172)

    المؤلفون: Schadendorf D., Ascierto P. A., Haanen J., Espinosa E., Demidov L., Garbe C., Guida M., Lorigan P., Chiarion-Sileni V., Gogas H., Maio M., Fierro M. T., Hoeller C., Terheyden P., Gutzmer R., Guren T. K., Bafaloukos D., Rutkowski P., Plummer R., Waterston A., Kaatz M., Mandala M., Marquez-Rodas I., Munoz-Couselo E., Dummer R., Grigoryeva E., Young T. C., Nathan P.

    المساهمون: Schadendorf D., Ascierto P.A., Haanen J., Espinosa E., Demidov L., Garbe C., Guida M., Lorigan P., Chiarion-Sileni V., Gogas H., Maio M., Fierro M.T., Hoeller C., Terheyden P., Gutzmer R., Guren T.K., Bafaloukos D., Rutkowski P., Plummer R., Waterston A., Kaatz M., Mandala M., Marquez-Rodas I., Munoz-Couselo E., Dummer R., Grigoryeva E., Young T.C., Nathan P.

    مصطلحات موضوعية: Advanced melanoma, Autoimmune, CNS metastasi, ECOG performance statu, Ipilimumab, Nivolumab

    العلاقة: info:eu-repo/semantics/altIdentifier/pmid/31581055; info:eu-repo/semantics/altIdentifier/wos/WOS:000490764300018; volume:121; firstpage:144; lastpage:153; numberofpages:10; journal:EUROPEAN JOURNAL OF CANCER; http://hdl.handle.net/2318/1717992Test; info:eu-repo/semantics/altIdentifier/scopus/2-s2.0-85072658755; http://www.journals.elsevier.com/european-journal-of-cancerTest/

    الإتاحة: https://doi.org/10.1016/j.ejca.2019.08.014Test
    http://hdl.handle.net/2318/1717992Test
    http://www.journals.elsevier.com/european-journal-of-cancerTest/

    View record in BASE

    أضف إلى المفضلة
  7. 47
    دورية أكاديمية
    Health-related quality of life in patients with fully resected BRAFV600 mutation–positive melanoma receiving adjuvant vemurafenib

    المؤلفون: Schadendorf D., Di Giacomo A. M., Demidov L., Merelli B., Bondarenko I., Ascierto P. A., Herbert C., Mackiewicz A., Rutkowski P., Guminski A., Goodman G. R., Simmons B., Ye C., Hong A., Lewis K.

    المساهمون: Schadendorf, D., Di Giacomo, A. M., Demidov, L., Merelli, B., Bondarenko, I., Ascierto, P. A., Herbert, C., Mackiewicz, A., Rutkowski, P., Guminski, A., Goodman, G. R., Simmons, B., Ye, C., Hong, A., Lewis, K.

    مصطلحات موضوعية: Adjuvant treatment, BRAF, Health-related quality of life, Resected melanoma, Vemurafenib, Adolescent, Adult, Aged, 80 and over, Anorexia, Antineoplastic Agent, Cognitive Dysfunction, Fatigue, Female, Human, Logistic Model, Male, Melanoma, Middle Aged, Pain, Proto-Oncogene Proteins B-raf, Skin Neoplasm, Young Adult, Chemotherapy, Adjuvant, Dermatologic Surgical Procedure, Quality of Life

    العلاقة: info:eu-repo/semantics/altIdentifier/pmid/31704549; info:eu-repo/semantics/altIdentifier/wos/WOS:000499645600019; volume:123; firstpage:155; lastpage:161; numberofpages:7; journal:EUROPEAN JOURNAL OF CANCER; http://hdl.handle.net/11365/1119739Test; info:eu-repo/semantics/altIdentifier/scopus/2-s2.0-85074348441

    الإتاحة: https://doi.org/10.1016/j.ejca.2019.09.019Test
    http://hdl.handle.net/11365/1119739Test

    View record in BASE

    أضف إلى المفضلة
  8. 48
    دورية أكاديمية
    Safety and efficacy of nivolumab in patients with rare melanoma subtypes who progressed on or after ipilimumab treatment: a single-arm, open-label, phase II study (CheckMate 172)

    المؤلفون: Nathan P, Ascierto PA, Haanen J, Espinosa E, Demidov L, Garbe C, Guida M, Lorigan P, Chiarion-Sileni V, Gogas H, Maio M, Fierro MT, Hoeller C, Terheyden P, Gutzmer R, Guren TK, Bafaloukos D, Rutkowski P, Plummer R, Waterston A, Kaatz M, MANDALA' M, Marquez-Rodas I, Muñoz-Couselo E, Dummer R, Grigoryeva E, Young TC, Schadendorf D

    المساهمون: Nathan, P, Ascierto, Pa, Haanen, J, Espinosa, E, Demidov, L, Garbe, C, Guida, M, Lorigan, P, Chiarion-Sileni, V, Gogas, H, Maio, M, Fierro, Mt, Hoeller, C, Terheyden, P, Gutzmer, R, Guren, Tk, Bafaloukos, D, Rutkowski, P, Plummer, R, Waterston, A, Kaatz, M, Mandala', M, Marquez-Rodas, I, Muñoz-Couselo, E, Dummer, R, Grigoryeva, E, Young, Tc, Schadendorf, D

    العلاقة: info:eu-repo/semantics/altIdentifier/wos/WOS:000486628600018; journal:EUROPEAN JOURNAL OF CANCER; http://hdl.handle.net/11391/1480919Test; info:eu-repo/semantics/altIdentifier/scopus/2-s2.0-85070912965

    الإتاحة: http://hdl.handle.net/11391/1480919Test

    View record in BASE

    أضف إلى المفضلة
  9. 49
    دورية أكاديمية
    Safety and efficacy of nivolumab in challenging subgroups with advanced melanoma who progressed on or after ipilimumab treatment: A single-arm, open-label, phase II study (CheckMate 172)

    المؤلفون: Schadendorf D, Ascierto PA, Haanen J, Espinosa E, Demidov L, Garbe C, Guida M, Lorigan P, Chiarion-Sileni V, Gogas H, Maio M, Fierro MT, Hoeller C, Terheyden P, Gutzmer R, Guren TK, Bafaloukos D, Rutkowski P, Plummer R, Waterston A, Kaatz M, MANDALA' M, Marquez-Rodas I, Muñoz-Couselo E, Dummer R, Grigoryeva E, Young TC, Nathan P

    المساهمون: Schadendorf, D, Ascierto, Pa, Haanen, J, Espinosa, E, Demidov, L, Garbe, C, Guida, M, Lorigan, P, Chiarion-Sileni, V, Gogas, H, Maio, M, Fierro, Mt, Hoeller, C, Terheyden, P, Gutzmer, R, Guren, Tk, Bafaloukos, D, Rutkowski, P, Plummer, R, Waterston, A, Kaatz, M, Mandala', M, Marquez-Rodas, I, Muñoz-Couselo, E, Dummer, R, Grigoryeva, E, Young, Tc, Nathan, P

    العلاقة: info:eu-repo/semantics/altIdentifier/wos/WOS:000490764300018; journal:EUROPEAN JOURNAL OF CANCER; http://hdl.handle.net/11391/1480881Test; info:eu-repo/semantics/altIdentifier/scopus/2-s2.0-85072658755

    الإتاحة: http://hdl.handle.net/11391/1480881Test

    View record in BASE

    أضف إلى المفضلة
  10. 50
    دورية أكاديمية
    Cobimetinib plus atezolizumab in BRAFV600 wild-type melanoma: primary results from the randomized phase III IMspire170 study

    المؤلفون: Gogas, H, Dréno, B, Larkin, J, Demidov, L, Stroyakovskiy, D, Eroglu, Z, Francesco Ferrucci, P, Pigozzo, J, Rutkowski, P, Mackiewicz, J, Rooney, I, Voulgari, A, Troutman, S, Pitcher, B, Guo, Y, Yan, Y, Castro, M, Mulla, S, Flaherty, K, Arance, A

    المساهمون: National and Kapodistrian University of Athens (NKUA), Centre Hospitalier Universitaire de Nantes = Nantes University Hospital (CHU Nantes), Centre d’Investigation Clinique de Nantes (CIC Nantes), Université de Nantes (UN)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre Hospitalier Universitaire de Nantes = Nantes University Hospital (CHU Nantes), Centre de Recherche en Cancérologie et Immunologie Nantes-Angers (CRCINA), Université d'Angers (UA)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS)-Centre Hospitalier Universitaire de Nantes = Nantes University Hospital (CHU Nantes)-Université de Nantes - UFR de Médecine et des Techniques Médicales (UFR MEDECINE), Université de Nantes (UN)-Université de Nantes (UN), Royal Marsden NHS Foundation Trust, N.N. Blokhin Russian Cancer Research Center, Moscow City Oncology Hospital No. 62 Moscow, Russia (MCOH), H. Lee Moffitt Cancer Center and Research Institute, European Institute of Oncology Milan (ESMO), Veneto Institute of Oncology IOV-IRCCS Padua, Italy, Maria Sklodowska-Curie National Research Institute of Oncology Krakow, Poland, Poznan University of Medical Sciences Poland (PUMS), Genentech, Inc. San Francisco, Roche Products Ltd, F. Hoffmann-La Roche Basel, Massachusetts General Hospital Cancer Center Boston, MA, USA, Harvard Medical School Boston (HMS), Hospital Clinic Barcelona, Spain

    المصدر: ISSN: 0923-7534.

    مصطلحات موضوعية: atezolizumab, cobimetinib, pembrolizumab, melanoma, BRAF wild-type, [SDV]Life Sciences [q-bio]

    العلاقة: info:eu-repo/semantics/altIdentifier/pmid/33309774; inserm-03710214; https://inserm.hal.science/inserm-03710214Test; https://inserm.hal.science/inserm-03710214/documentTest; https://inserm.hal.science/inserm-03710214/file/PIIS092375342043203X.pdfTest; PUBMED: 33309774

    الإتاحة: https://doi.org/10.1016/j.annonc.2020.12.004Test
    https://inserm.hal.science/inserm-03710214Test
    https://inserm.hal.science/inserm-03710214/documentTest
    https://inserm.hal.science/inserm-03710214/file/PIIS092375342043203X.pdfTest

    View record in BASE

    أضف إلى المفضلة
أدوات البحث: أحصل على تغذية RSS — أرسل هذا البحث بالبريد الإلكتروني — حفظ البحث